Terms: = Germ cell tumor AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
1016 results:
1. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
2. Identification of prognostic m6A modification patterns and score system in melanoma patients.
Wang F; Chen P; Ouyang S; Xiong K; Liu Z; Wang Y
Medicine (Baltimore); 2024 Apr; 103(17):e37950. PubMed ID: 38669381
[TBL] [Abstract] [Full Text] [Related]
3. Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.
Qin L; Zhang G; Wu Y; Yang Y; Zou Z
Cancer Immunol Immunother; 2024 Apr; 73(6):103. PubMed ID: 38630135
[TBL] [Abstract] [Full Text] [Related]
4. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract] [Full Text] [Related]
5. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract] [Full Text] [Related]
6. Analyses of tertiary lymphoid structures observed in cases of Merkel cell carcinoma showing spontaneous regression.
Nakamura M; Yoshimitsu M; Magara T; Kano S; Kato H; Morita A
Exp Dermatol; 2024 Mar; 33(3):e15062. PubMed ID: 38532566
[TBL] [Abstract] [Full Text] [Related]
7. An advanced comprehensive muti-cell-type-specific model for predicting anti-PD-1 therapeutic effect in melanoma.
Sun W; Zhu Y; Zou Z; Wang L; Zhong J; Shen K; Lin X; Gao Z; Liu W; Li Y; Xu Y; Ren M; Hu T; Wei C; Gu J; Chen Y
Theranostics; 2024; 14(5):2127-2150. PubMed ID: 38505619
[No Abstract] [Full Text] [Related]
8. Targeting Wnt signaling for improved glioma immunotherapy.
Gutova M; Hibbard JC; Ma E; Natri HM; Adhikarla V; Chimge NO; Qiu R; Nguyen C; Melendez E; Aguilar B; Starr R; Yin H; Rockne RC; Ono M; Banovich NE; Yuan YC; Brown CE; Kahn M
Front Immunol; 2024; 15():1342625. PubMed ID: 38449858
[TBL] [Abstract] [Full Text] [Related]
9. Merkel cell Carcinoma of Unknown Primary Origin.
Francetić H; Simetić L; Tomasović Lončarić Č; Štulhofer Buzina D; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(3):153-155. PubMed ID: 38439727
[TBL] [Abstract] [Full Text] [Related]
10. Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug-resistant gestational trophoblastic neoplasia: Four case reports and literature review.
Liu W; Zhu Y; Wang Y; Li R; Zou D; Chen R; Yang L; Huang Y
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2016. PubMed ID: 38425251
[TBL] [Abstract] [Full Text] [Related]
11. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression.
Hai Y; Fan R; Zhao T; Lin R; Zhuang J; Deng A; Meng S; Hou Z; Wei G
Pharmacol Res; 2024 Apr; 202():107115. PubMed ID: 38423231
[TBL] [Abstract] [Full Text] [Related]
12. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract] [Full Text] [Related]
13. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract] [Full Text] [Related]
14. tumor-targeted nanodrug FSGG/siGal-9 for transdermal photothermal immunotherapy of melanoma.
Ren H; Zhang Y; Huang W; Xu H; He W; Hao N; Zhang C
Commun Biol; 2024 Feb; 7(1):188. PubMed ID: 38366083
[TBL] [Abstract] [Full Text] [Related]
15. Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit cell Growth, and Reduce Invasive Capability in Melanoma cell Lines.
Zanrè V; Bellinato F; Cardile A; Passarini C; Monticelli J; Di Bella S; Menegazzi M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338893
[TBL] [Abstract] [Full Text] [Related]
16. tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.
Lien SC; Ly D; Yang SYC; Wang BX; Clouthier DL; St Paul M; Gadalla R; Noamani B; Garcia-Batres CR; Boross-Harmer S; Bedard PL; Pugh TJ; Spreafico A; Hirano N; Razak ARA; Ohashi PS
Nat Commun; 2024 Feb; 15(1):1094. PubMed ID: 38321065
[TBL] [Abstract] [Full Text] [Related]
17. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
18.
Zhou S; Zhang S; Zheng K; Li Z; Hu E; Mu Y; Mai J; Zhao A; Zhao Z; Li F
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302417
[TBL] [Abstract] [Full Text] [Related]
19. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract] [Full Text] [Related]
20. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Baginska J; Nau A; Gomez Diaz I; Giobbie-Hurder A; Weirather J; Vergara J; Abrecht C; Hallisey M; Dennis J; Severgnini M; Huezo J; Marciello I; Rahma O; Manos M; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Ott PA; Buchbinder EI; Hodi FS
Cancer Immunol Immunother; 2024 Jan; 73(1):17. PubMed ID: 38236249
[TBL] [Abstract] [Full Text] [Related]
[Next]
